AMCS/QUENTIC
5.7.2022 13:02:05 CEST | Business Wire | Press release
The German regulatory authorities have approved the sale of the Quentic GmbH to the AMCS Group. The transaction is hence closed and Quentic will be a part of AMCS as of July 2022.
AMCS, the leading global supplier of integrated software and vehicle technology for the environmental, utility, waste, recycling, and resource industries, and Quentic, one of the leading solution providers of Software as a Service for EHSQ and ESG management, announced the acquisition of Quentic by AMCS on May 12, 2022. As the regulatory authorities have now approved the transaction, the acquisition of the Berlin-based software provider for occupational safety, environmental, sustainability, and quality management took effect on June 30, 2022. "With this step, we open a new chapter in our 15-year company history," explains Markus Becker, CEO of Quentic. "The cooperation will further strengthen Quentic's growth of the past years. We particularly look forward to the professional collaboration and exchange in order to jointly provide the best digital business solutions for a healthier, cleaner and more sustainable future."
Technology portfolio for sustainable business processes
With the addition of Quentic to its portfolio, AMCS expands its offering of promising digital solutions that optimize workflows and have a direct positive impact on the environment. "Regardless of the industry, digitalization is a key enabler on the path to a global and sustainable circular economy," confirms Jimmy Martin CEO of AMCS. "With the variety of solutions in the AMCS portfolio, we aim to put these technologies at the fingertips of our customers. Integrated management of all processes related to occupational safety, environmental, sustainability and quality management, as offered by the Quentic SaaS platform and app, is therefore a valuable addition to our offering," Martin continues.
Becoming a market leader with sustainable growth
Markus Becker, Sebastian Mönnich and Hardy Menzel founded Quentic in 2007. Today, the company employs more than 250 people at 14 locations across Europe. More than 900 companies strengthen their processes in the areas of occupational safety, environmental, sustainability and quality management with Quentic software solutions. Business angels and financial investors supported the company’s growth in several rounds of financing. "We would like to thank our long-term partners One Peak, Morgan Stanley Expansion Capital and High-Tech Gründerfonds for the trustful and valuable cooperation. Together we have successfully put Quentic on the path to becoming the European market leader for EHSQ and ESG-management software and services. Now we are looking forward to continue on this path with AMCS," explains Markus Becker. The Quentic management team will continue to shape the company’s future together with the new owner AMCS.
About AMCS
AMCS is headquartered in Limerick, Ireland with offices in North America, Europe, and Australia employing over 1000 people across 18 countries. AMCS is a global leader of integrated software and vehicle technology for the environmental, recycling, and resource industries and offers optimization solutions to the broader transport and logistics market. AMCS helps over 4,000 customers globally to reduce their operating costs, increase asset utilization, optimize margins, and improve customer service. Their enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world.
About Quentic
Quentic is one of the leading solution providers of Software as a Service (SaaS) for EHSQ and ESG management. The Quentic platform comprises ten individually combinable modules and offers an ideal way for companies to manage Health & Safety, Risks & Audits, Incidents & Observations, Hazardous Chemicals, Control of Work, Legal Compliance, Online Instructions, Processes, Environmental Management and Sustainability.
The company is headquartered in Berlin, Germany, and employs more than 250 people. Branch offices are located in Germany, Austria, Switzerland, Finland, Sweden, Denmark, Belgium, the Netherlands, France, Spain and Italy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom